STEMI-The importance of balance between antithrombotic treatment and bleeding risk

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11140%2F13%3A10134385" target="_blank" >RIV/00216208:11140/13:10134385 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00669806:_____/13:10134385

Výsledek na webu

<a href="http://dx.doi.org/10.1016/j.crvasa.2013.02.004" target="_blank" >http://dx.doi.org/10.1016/j.crvasa.2013.02.004</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.crvasa.2013.02.004" target="_blank" >10.1016/j.crvasa.2013.02.004</a>

Jazyk výsledku

angličtina

Název v původním jazyce

STEMI-The importance of balance between antithrombotic treatment and bleeding risk

Popis výsledku v původním jazyce

The incidence of ST elevation myocardial infarction (STEMI) is around 66 STEMI per 100 000 of population/year, with 6-12% hospital mortality in unselected patients [1]. Modern treatment strategies for STEMI are based on immediate antithrombotic treatmentand primary percutaneous coronary intervention (PCI) with stent implantation. Therapy with a combination of two or even three more potent antiplatelet and anticoagulant agents reduces both short-term and long-term ischemic risk, morbidity and mortality;on the other hand it is associated with higher risks of bleeding. The first part of this review is focused on the pathogenesis of thrombi in STEMI patients and antithrombotic drugs currently used to treat STEMI patients. In the second part we discuss several factors that can affect bleeding risks including the choice of access site for coronary angiography, prevention and treatment of bleeding in STEMI patients. Finding a balance which minimizes both thrombotic and bleeding risk is cruc

Název v anglickém jazyce

STEMI-The importance of balance between antithrombotic treatment and bleeding risk

Popis výsledku anglicky

The incidence of ST elevation myocardial infarction (STEMI) is around 66 STEMI per 100 000 of population/year, with 6-12% hospital mortality in unselected patients [1]. Modern treatment strategies for STEMI are based on immediate antithrombotic treatmentand primary percutaneous coronary intervention (PCI) with stent implantation. Therapy with a combination of two or even three more potent antiplatelet and anticoagulant agents reduces both short-term and long-term ischemic risk, morbidity and mortality;on the other hand it is associated with higher risks of bleeding. The first part of this review is focused on the pathogenesis of thrombi in STEMI patients and antithrombotic drugs currently used to treat STEMI patients. In the second part we discuss several factors that can affect bleeding risks including the choice of access site for coronary angiography, prevention and treatment of bleeding in STEMI patients. Finding a balance which minimizes both thrombotic and bleeding risk is cruc

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FA - Kardiovaskulární nemoci včetně kardiochirurgie

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2013

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Cor et Vasa

ISSN

0010-8650

e-ISSN

—

Svazek periodika

55

Číslo periodika v rámci svazku

2

Stát vydavatele periodika

CZ - Česká republika

Počet stran výsledku

13

Strana od-do

"E135"-"E146"

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—